학술논문

Low-frequency stimulation of the tuberomammillary nucleus facilitates electrical amygdaloid-kindling acquisition in Sprague-Dawley rats
Document Type
Academic Journal
Source
Neurobiology of Disease. Oct, 2008, Vol. 32 Issue 1, p151, 6 p.
Subject
Seizures (Medicine)
Language
English
ISSN
0969-9961
Abstract
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.nbd.2008.07.002 Byline: Deng-Chang Wu (a), Zheng-Bing Zhu-Ge (a)(b), Chao-Yang Yu (a)(b), Qi Fang (a), Shuang Wang (a)(c), Chun-Lei Jin (a), Shi-Hong Zhang (a), Zhong Chen (a) Keywords: Tuberomammillary nucleus; Epilepsy; Deep brain stimulation; Low-frequency stimulation; Kindling; Pentylenetetrazol; Maximal electroshock Abstract: Histamine plays a suppressive role in seizure. The tuberomammillary nucleus (TM) is the only locus of histaminergic neurons in the brain. To determine whether deep brain stimulation (DBS) of the TM provides protection against seizures, we tested the effects of low-frequency stimulation (LFS, 1 Hz), high frequency stimulation (HFS, 100 Hz), and electrolytic lesions of the TM on seizures generated by amygdaloid kindling, pentylenetetrazol (PTZ) and maximal electroshock (MES) in rats. LFS of TM accelerated the progression of behavioral seizure stage and increased the mean afterdischarge duration (ADD) during acquisition of amygdaloid-kindling seizures, but had no considerable anticonvulsive effect in fully kindled animals. It augmented the MES-induced seizures as well, but had no appreciable effects on PTZ-kindled seizures. In addition, both HFS and bilateral lesions of the TM exacerbated the progression of amygdaloid-kindling seizures. These results suggest that specific negative sites for DBS exist in the brain, such as the TM. This study indicates that it is crucial to choose a suitable target for DBS in the clinical treatment of epilepsy. Author Affiliation: (a) Department of Pharmacology, Institute of Neuroscience, School of Medicine, Zhejiang University, 388 Yuhang Tang Road, Hangzhou, 310058, China (b) Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China (c) Department of Neurology, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China Article History: Received 9 March 2008; Revised 8 June 2008; Accepted 3 July 2008